---
title: "Nurtec ODT (rimegepant), all indications: Drug interactions questions"
description: "Drug interactions questions on Nurtec ODT (rimegepant) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What drug interactions does Nurtec ODT have? How much do CYP3A4 inhibitors like itraconazole raise Nurtec ODT levels? Can Nurtec ODT be taken with CYP3A inducers like rifampin? Does Nurtec ODT interact with birth control pills? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/nurtec-odt/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nurtec ODT (rimegepant), all indications: Drug interactions questions

Manufacturer: Pfizer Inc  
Prescribing information: [Nurtec ODT](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036)  
Indication pages: [Acute treatment of migraine](https://www.evicenter.com/medical-information/nurtec-odt--acute-treatment-of-migraine)

## Drug interactions

<a id="nurtec-drug-interactions"></a>

### What drug interactions does Nurtec ODT have?

> “Concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4 results in a significant increase in rimegepant exposure. Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4 [see Clinical Pharmacology (12.3)].
>
> Concomitant administration of NURTEC ODT with moderate inhibitors of CYP3A4 may result in increased exposure of rimegepant. Avoid another dose of NURTEC ODT within 48 hours when it is concomitantly administered with moderate inhibitors of CYP3A4 [see Clinical Pharmacology (12.3)].
>
> 7.2 CYP3A Inducers
>
> Concomitant administration of NURTEC ODT with strong or moderate inducers of CYP3A can result in a significant reduction in rimegepant exposure, which may lead to loss of efficacy of NURTEC ODT. Avoid concomitant administration of NURTEC ODT with strong or moderate inducers of CYP3A [see Clinical Pharmacology (12.3)].
>
> 7.3 P-gp Inhibitors
>
> Concomitant administration of NURTEC ODT with potent inhibitors of P-gp (e.g., amiodarone, cyclosporine, lapatinib, quinidine, ranolazine) may result in increased exposure of rimegepant. Avoid another dose of NURTEC ODT within 48 hours when it is concomitantly administered with potent inhibitors of P-gp [see Clinical Pharmacology (12.3)].”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=7.1%20CYP3A4%20Inhibitors-,Concomitant%20administration%20of%20NURTEC%20ODT%20with%20strong%20inhibitors%20of%20CYP3A4,P%2Dgp%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

<a id="nurtec-cyp3a4-inhibitors"></a>

### How much do CYP3A4 inhibitors like itraconazole raise Nurtec ODT levels?

> “In a dedicated drug interaction study, concomitant administration of 75 mg rimegepant (single dose) with itraconazole, a strong CYP3A4 inhibitor, at steady state resulted in increased exposures of rimegepant (AUC by 4-fold and Cmax by ~1.5-fold) [see Drug Interactions (7.1)]. No dedicated drug interaction study was conducted to assess the effect of concomitant administration of a weak inhibitor of CYP3A4 on the pharmacokinetics of rimegepant. The concomitant administration of rimegepant with a moderate inhibitor of CYP3A4 may increase rimegepant exposures (AUC) by less than 2-fold [see Drug Interactions (7.1)]. Concomitant administration of rimegepant with a weak inhibitor of CYP3A4 is not expected to have a clinically significant impact on rimegepant exposures.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=In%20a%20dedicated%20drug%20interaction,significant%20impact%20on%20rimegepant%20exposures.)

> “In a dedicated drug interaction study, concomitant administration of 75 mg rimegepant (single dose) with fluconazole, a combined moderate CYP3A4 and CYP2C9 inhibitor, resulted in increased exposures of rimegepant (AUC by 1.8-fold) with no relevant effect on Cmax. Rimegepant is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9. Increase in the exposure of rimegepant can be attributed to combined inhibition of CYP2C9 and CYP3A4 with fluconazole administration suggesting a minor contribution from CYP2C9. Thus, CYP2C9 inhibition alone is not expected to significantly affect rimegepant exposures.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=CYP2C9%20Inhibitors-,In%20a%20dedicated%20drug%20interaction%20study%2C%20concomitant%20administration%20of%2075,to%20significantly%20affect%20rimegepant%20exposures.)

<a id="nurtec-cyp3a-inducers"></a>

### Can Nurtec ODT be taken with CYP3A inducers like rifampin?

> “In a dedicated drug interaction study, concomitant administration of 75 mg rimegepant (single dose) with rifampin, a strong CYP3A4 inducer, at steady state resulted in decreased exposures of rimegepant (AUC by 80% and Cmax by 64%), which may lead to loss of efficacy [see Drug Interactions (7.2)]. No dedicated drug interaction study was conducted to assess the effect of concomitant administration of a moderate or weak inducer of CYP3A4 on the pharmacokinetics of rimegepant. Since rimegepant is a moderately sensitive substrate for CYP3A4, drugs that are moderate inducers of CYP3A4 can also cause significant reduction in rimegepant exposure resulting in loss of efficacy [see Drug Interactions (7.2)]. Clinically significant interaction is not expected with concomitant administration of weak inducers of CYP3A4 and rimegepant.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=CYP3A%20Inducers-,In%20a%20dedicated%20drug%20interaction%20study%2C%20concomitant%20administration%20of%2075,inducers%20of%20CYP3A4%20and%20rimegepant.)

<a id="nurtec-birth-control"></a>

### Does Nurtec ODT interact with birth control pills?

> “Other Drugs: No significant pharmacokinetic interactions were observed when rimegepant was concomitantly administered with oral contraceptives (norelgestromin, ethinyl estradiol), midazolam (a sensitive CYP3A4 substrate), metformin (a MATE1 substrate), or sumatriptan [see Clinical Pharmacology (12.2)].”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Other%20Drugs%3A%20No%20significant%20pharmacokinetic,sumatriptan%20%5Bsee%20Clinical%20Pharmacology%20%2812.2%29%5D.)

> “No restrictions for patients taking oral contraceptives¹”

Source: [NURTEC ODT: Dosing | NURTEC® ODT (rimegepant) | For HCPs | Safety Info, captured 2026-11-13](https://nurtec.pfizerpro.com/dosing#:~:text=No%20restrictions%20for%20patients%20taking%20oral%20contraceptives%C2%B9)

<a id="nurtec-with-triptans"></a>

### Does Nurtec ODT interact with sumatriptan?

> “No clinically relevant differences in resting blood pressure were observed when rimegepant was concomitantly administered with sumatriptan (12 mg subcutaneous, given as two 6 mg doses separated by one hour) compared with sumatriptan alone to healthy volunteers.”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=No%20clinically%20relevant%20differences%20in,sumatriptan%20alone%20to%20healthy%20volunteers.)

> “Other Drugs: No significant pharmacokinetic interactions were observed when rimegepant was concomitantly administered with oral contraceptives (norelgestromin, ethinyl estradiol), midazolam (a sensitive CYP3A4 substrate), metformin (a MATE1 substrate), or sumatriptan [see Clinical Pharmacology (12.2)].”

Source: [NURTEC ODT: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19036#:~:text=Other%20Drugs%3A%20No%20significant%20pharmacokinetic,sumatriptan%20%5Bsee%20Clinical%20Pharmacology%20%2812.2%29%5D.)

Note: These are pharmacology study results in healthy volunteers. In Study 1, triptans were not allowed as rescue medication within 48 hours of the study dose.

## Related pages
- [Medical information: Nurtec ODT (rimegepant): All indications](https://www.evicenter.com/medical-information/nurtec-odt)
- [Indication](https://www.evicenter.com/medical-information/nurtec-odt/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/nurtec-odt/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/nurtec-odt/safety)
- [Specific populations](https://www.evicenter.com/medical-information/nurtec-odt/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/nurtec-odt/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/nurtec-odt/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/nurtec-odt/access-and-coverage)
